279 related articles for article (PubMed ID: 28044990)
1. Unfractionated heparin versus bivalirudin in patients undergoing primary percutaneous coronary intervention: a SWEDEHEART study.
Grimfjärd P; Erlinge D; Koul S; Lagerqvist B; Svennblad B; Varenhorst C; James SK
EuroIntervention; 2017 Mar; 12(16):2009-2017. PubMed ID: 28044990
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
4. Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial.
Schoos MM; De Luca G; Dangas GD; Clemmensen P; Ayele GM; Mehran R; Stone GW
EuroIntervention; 2016 Oct; 12(9):1144-1153. PubMed ID: 27753600
[TBL] [Abstract][Full Text] [Related]
5. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
[TBL] [Abstract][Full Text] [Related]
6. Bivalirudin versus heparin with primary percutaneous coronary intervention.
Venetsanos D; Lawesson SS; James S; Koul S; Erlinge D; Swahn E; Alfredsson J
Am Heart J; 2018 Jul; 201():9-16. PubMed ID: 29910059
[TBL] [Abstract][Full Text] [Related]
7. Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction.
Faulkenberg KD; Beavers JC; Finks SW
Ann Pharmacother; 2016 Feb; 50(2):141-51. PubMed ID: 26681442
[TBL] [Abstract][Full Text] [Related]
8. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
[TBL] [Abstract][Full Text] [Related]
9. Bivalirudin during primary PCI in acute myocardial infarction.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
[TBL] [Abstract][Full Text] [Related]
10. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial.
Zeymer U; van 't Hof A; Adgey J; Nibbe L; Clemmensen P; Cavallini C; ten Berg J; Coste P; Huber K; Deliargyris EN; Day J; Bernstein D; Goldstein P; Hamm C; Steg PG
Eur Heart J; 2014 Sep; 35(36):2460-7. PubMed ID: 24849104
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials.
Lipinski MJ; Lhermusier T; Escarcega RO; Baker NC; Magalhães MA; Torguson R; Suddath WO; Satler LF; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2014; 15(6-7):315-22. PubMed ID: 25440505
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
[TBL] [Abstract][Full Text] [Related]
14. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States.
Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Shah RM; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
JACC Cardiovasc Interv; 2016 Dec; 9(23):2376-2386. PubMed ID: 27838271
[TBL] [Abstract][Full Text] [Related]
15. Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention.
Fiedler KA; Ndrepepa G; Schulz S; Floh S; Hoppmann P; Kufner S; Bernlochner I; Byrne RA; Schunkert H; Laugwitz KL; Kastrati A
EuroIntervention; 2016 Feb; 11(11):e1275-82. PubMed ID: 26865445
[TBL] [Abstract][Full Text] [Related]
16. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Feldman DN; Wong SC; Bergman G; Minutello RM
J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
[TBL] [Abstract][Full Text] [Related]
17. Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Koutouzis M; Lagerqvist B; James S; Omerovic E; Matejka G; Grip L; Albertsson P
Heart; 2011 Sep; 97(18):1484-8. PubMed ID: 21487123
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.
Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS
Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
